Goodwin Procter LLP advised Pear Therapeutics on the deal.Pear Therapeutics announced its definitive business combination agreement with Thimble Point Acquisition Corp. (Nasdaq: THMA), a special purpose acquisition…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
